arrow
A

Angelo Dipasquale

IRCCS Humanitas Research Hospital
H指数:15
被引数:467

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TET CpG sequence-context-specific DNA demethylation shapes progression of IDH-mutant gliomas

TET CpG序列上下文特异性DNA去甲基化调控IDH突变型胶质瘤的进展

2026-03-170
OAAI
Reasons driving choice and clinical course of patients with CNS WHO grade 3 IDH mutant glioma receiving vorasidenib after surgery: a pilot experience

手术后接受vorasidenib的CNS 3级IDH突变型胶质瘤患者的驾驶选择和临床过程的原因: 试点经验

2026-01-280
PRE
A PHASE 1, FIRST-IN-HUMAN STUDY OF REGORAFENIB PLUS TEMOZOLOMIDE WITH OR WITHOUT RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED, IDH WILDTYPE GLIOBLASTOMA: THE REGOMA-2 TRIAL

一项关于瑞戈非尼联合替莫唑胺,在有或无放疗情况下,用于新诊断的MGMT甲基化、IDH野生型胶质母细胞瘤患者的I期首个人类研究:REGOMA-2试验

2025-11-010
OAAI
EFFECTIVENESS OF TARGET THERAPY IN ADULT AND PEDIATRIC RECURRENT HIGH GRADE GLIOMA PATIENTS WITH BRAFV600E MUTATION OR NTRK FUSION: A REAL-LIFE MULTICENTRIC ITALIAN ANALYSIS.

靶向疗法在成人及儿科复发性高级别胶质瘤患者(携带BRAFV600E突变或NTRK融合)中的有效性:一项意大利多中心真实世界分析。

2025-10-010
OAAI
A PHASE 1, FIRST-IN-HUMAN STUDY OF REGORAFENIB PLUS TEMOZOLOMIDE WITH OR WITHOUT RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED, IDH WILDTYPE GLIOBLASTOMA: REGOMA-2 TRIAL

一项关于瑞戈非尼联合替莫唑胺,无论是否联用放疗,在 newly diagnosed MGMT methylated, IDH wildtype glioblastoma 患者中的首次人体研究的第1阶段:REGOMA-2试验

2025-10-010
OAAI
Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse events

免疫检查点抑制剂治疗患者中心脏不良事件的MRI研究:一项前瞻性队列研究

2025-03-180
OA
Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors

揭示循环肿瘤细胞的影响: 实体瘤的二十年发现和临床进展

2024-11-010
PRE
The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study

辅助化疗在H3K27改变的弥漫性中线胶质瘤患者中的作用: 多中心回顾性研究

2024-03-082
PRE
Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram

使用新颖且外部验证的预后列线图,为下一代免疫治疗早期临床试验优化患者选择

2024-01-150
OAAI